TG4010
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Cancer vaccines and oncolytic immunotherapy are promising treatment strategies with potential to provide greater clinical benefit…
One of the strategies to enhance immune response against tumors has been the use of vaccines against tumor-associated antigens…
Cancer immunotherapy has clearly taken its place in the clinic as one pillar of cancer care. Immune checkpoint blockade, which…
Non-small-cell lung cancer usually carries a dismal prognosis. Novel treatment approaches are clearly warranted. Immunotherapy…
TG4010 is a therapeutic cancer vaccine based on a viral vector, a modified vaccinia of Ankara (MVA), expressing MUC1 as well as…
3027 Background: TG4010 is a targeted immunotherapy product. It was tested in combination with first-line chemotherapy in a…
8023 Background: TG4010 is a recombinant Modified Virus Ankara (MVA) expressing both IL2 and the tumor-associated antigen MUC1…
Vaccines are well known in the context of prevention of diseases caused by infectious agents. Current research is now aimed at…
4518 Background: Over-expression, non-polarity and under-glycosylation of the mucin glycoprotein molecule, MUC1, are associated…